Azzad Asset Management Inc. ADV acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 8,105 shares of the company's stock, valued at approximately $1,824,000.
A number of other large investors have also bought and sold shares of COR. Rise Advisors LLC bought a new stake in shares of Cencora in the first quarter valued at about $25,000. New Millennium Group LLC acquired a new position in Cencora during the 2nd quarter worth approximately $26,000. TCTC Holdings LLC bought a new position in shares of Cencora during the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC bought a new stake in shares of Cencora in the first quarter worth $30,000. Finally, LRI Investments LLC bought a new stake in shares of Cencora in the first quarter worth $31,000. 97.52% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on COR. Evercore ISI lowered their price target on shares of Cencora from $270.00 to $250.00 and set an "outperform" rating on the stock in a research note on Tuesday. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Wells Fargo & Company raised their price target on Cencora from $236.00 to $249.00 and gave the company an "equal weight" rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. boosted their price target on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 21st. Finally, Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $259.44.
Read Our Latest Stock Analysis on COR
Cencora Stock Performance
Shares of NYSE COR traded up $1.30 during mid-day trading on Tuesday, reaching $220.80. 1,598,843 shares of the company were exchanged, compared to its average volume of 1,416,660. Cencora, Inc. has a twelve month low of $182.62 and a twelve month high of $247.66. The stock has a market capitalization of $44.04 billion, a P/E ratio of 24.16, a P/E/G ratio of 1.58 and a beta of 0.44. The company's 50-day simple moving average is $234.25 and its 200-day simple moving average is $231.76. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93.
Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm's quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.92 earnings per share. As a group, research analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current year.
Cencora Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.92%. The ex-dividend date was Friday, August 9th. Cencora's dividend payout ratio (DPR) is 22.32%.
Insiders Place Their Bets
In other Cencora news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares of the company's stock, valued at $63,323,746.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares in the company, valued at approximately $63,323,746.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares of the company's stock, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,450,399 shares of company stock worth $1,070,392,799 in the last quarter. Corporate insiders own 15.80% of the company's stock.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Recommended Stories
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report